

P&T Committee Meeting Minutes

Subject:	Louisiana Department of Health and Hospitals Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 3118
Date:	October 29, 2014
Members Present:	<ul style="list-style-type: none"> ▪ Rochelle Dunham ▪ Jill Comeau, PharmD ▪ Jeff Deyo, MD ▪ Julio Figueroa, MD ▪ James Lu, MD ▪ Rebecca Gee, MD ▪ Amy Givler, MD ▪ Martha Harris, PharmD ▪ Ed Mader, MD ▪ Marty R. McKay, RPh ▪ Fred Mills, RPh ▪ Ben Orlando ▪ Roger Pope ▪ Neil Wolfson, MD
DHH Pharmacy Program Staff Present:	<ul style="list-style-type: none"> ▪ Melwyn Wendt, RPh ▪ Germaine Becks-Moody, PhD, BHSF Program Manager ▪ Sue Fontenot ▪ Mary Johnson ▪ Paul Knecht ▪ Kim Sullivan
Contractors Present:	<ul style="list-style-type: none"> ▪ Julie Pritchard, PharmD, Magellan Medicaid Administration ▪ Jennifer Pickett, Certified Court Reporter
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:05 a.m.

Parliamentary Business

1. **Introduction of Members and Roll Call.** Committee members and staff introduce themselves.
2. **Approval of Minutes.** Mr. McKay asked for a motion to approve the minutes. Dr. Wolfson offered a motion to approve the minutes. Dr. Orlando seconded the motion, which passed.

Reports

1. **Background.** Ms. Sullivan provides the background of forming the committee. Established under Louisiana Revised Statute 45:153.3. Purpose is to develop a Preferred Drug List with no prior authorization, make recommendations for additions and deletions for the Preferred Drug List, to advise the Secretary of DHH on policy recommendation related to the administration of the Medicaid Pharmacy Program. The committee consists of 21 members appointed by the Governor and confirmed by the Senate. The committee must abide by the code of governmental ethics. Bylaws to stay the same at this time. No statutory updates. Proposed bylaws will be sent out two weeks prior to the next meeting. Members can vote to amend bylaws.
2. **Code of Ethics.** Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. Section 115 prohibits a public servant from soliciting or accepting anything of economic value from any person who has contractual business or a financial relationship with the agency. Committee members cannot receive honorariums, reimbursements, or compensation of any kind including grants from pharmaceutical companies that have items on the Preferred Drug List or matters before the committee. A P&T Committee member can attend conferences and seminars put on by drug companies that have items on the Preferred Drug List or matters before the P&T Committee, as long as the member pays their own expenses for the trip. Committee members who are employees of a university cannot solicit grants on behalf of the university. Members do not have to file financial disclosure statements. If anyone has personal ethical questions, please visit the Board of Ethics at <http://www.ethics.state.la.us/> or contact Kim Sullivan at: Kimberly.sullivan@la.gov.
3. **Melwyn Wendt from DHH provides report.** Ms. Wendt called committee members attention to the packet they received with the Prior Authorization (PA) monthly report. Also in the packet is the Preferred Drug List that was from the May 7, 2014 meeting.
4. **Mary Johnson from DHH provides a Managed Care update.** Ms Johnson reported that the mandate is for all lives to move to MCOs. By August 1, 2015 all MCOs to have a shared MCO formulary.

New Business

1. **Dr. Pritchard** provides an overview of the TOP\$ program to the committee.
2. **Public Testimony.** In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review of Therapeutic Classes.

Presenter	Representing	Drug/Issue
Mike Barber	Synovia	Latuda
Rod Tate	Forrest Laboratories	Abilify Maintena
Megan Jones		Invega Sustenna
Brittany Howard	Mental Health America of Louisiana	Open access to antipsychotics
Nicole McGee	National Alliance of Mental Illness	Open access to antipsychotics
Anne Wicker	Pfizer	Xeljanz
Nina	Astra Zeneca	Pulmicort Flexhaler
Shane Perilloux		QNasal
Anne Wicker	Pfizer	Lyrica
Meghan Jones	Janssen	Invokamet
Unknown name		Sivextro
Fran Kaiser	Merck	Zontivity
**NOTE: other speakers were present, but if their drug was recommended as PDL, they yielded their time back and the names were not captured.		

I. Therapeutic Class Reviews

Thirty-eight (38) therapeutic classes were reviewed. Mr. McKay explained the Committee's review procedures. Monograph summaries were sent to the Committee prior to the meeting. Public comment was received for each therapeutic class prior to Committee discussion and action in accordance with state law and the P&T Committees Bylaws. Committee Proceedings Follow.

Alzheimer's Agents

Dr. Deyo makes the motion to accept. Dr. Wolfson seconds the motion. After discussion, a roll call vote was taken and the original motion passed with all in favor.

Committee recommendations for the PDL are:

- Donepezil
- Donepezil ODT
- Exelon patch

Antidepressants, Other

Dr. Deyo makes a motion to accept the recommendations. Dr. Figueroa seconds the motion. Roll call was taken and the motion passed with all in favor.

Committee recommendations for the PDL are:

- All Forms of Generic Bupropion
- Mirtazapine and ODT
- Phenzelzine
- Trazodone
- Venlafaxine
- Venlafaxine ER capsule

Antidepressants, SSRI

Dr. Figueroa makes the motion to accept, Dr. Wolfson seconds the motion. A roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Citalopram tab and soln
- Escitalopram tab
- Fluoxetine tab, soln, caps
- Fluvoxamine
- Paroxetine tab
- Sertraline tab and soln

Antihistamines, Minimally Sedating

Dr. Givler makes the motion to accept, Dr. Mader seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Cetirizine
- Levocetirizine
- Loratadine

Antihypertensive

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Catapres-TTS patch
- Clonidine generic
- Guanfacine
- Methyldopa
- Methyldopa/Hydrochlorothiazide oral

Antihyperuricemics

Dr. Figueroa makes the motion to accept, Dr. Harris seconds the motion. After discussion and no pharmaceutical manufacturers' requests to make presentations, the motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Allopurinol
- Probenecid
- Probenecid combination with Colchicine

Antiparkinson's

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Benztropine
- Carbidopa/levodopa

- Pramipexole
- Ropinirole
- Selegiline tab/cap
- Stelevo
- Trihexyphenidyl tab/elixir

Antipsoriatics, Oral

Dr. Wolfson makes the motion to accept, Dr. Figueroa seconds, there was no discussion and no speakers, roll call was taken and the motion passed.

Committee recommendations for the PDL are:

- Soriatane

Topical Antipsoriatics

Dr. Orlando makes the motion to accept, Dr. Figueroa seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Calcipotriene ointment, cream, and solution

Antipsychotics

Dr. Figueroa makes the motion to accept, Dr. Wolfson seconds the motion. After the public speakers, roll call was taken and the motion carried to accept the proposed list.

Committee recommendations for the PDL are:

- | | |
|-------------------------------------|----------------------------|
| • Amitriptyline/perphenazine oral | • Olanzapine tab/ODT |
| • Chlorpromazine oral | • Orap |
| • Clozapine oral | • Perphenazine oral |
| • Fluphenazine tab/inj | • Risperdal Consta inj |
| • Haloperidol lactate conc/oral/inj | • Risperidone tab/soln/ODT |
| • Haloperidol decanoate inj | • Seroquel XR |
| • Latuda oral | • Thioridazine oral |
| • Loxapine oral | • Thiothixene oral |
| • Quetiapine oral | • Trifluoperazine oral |
| • Invega Sustenna | • Ziprasidone cap |
| • Geodon IM | |

Anxiolytics

Dr. Orlando makes the motion to accept, Dr. Mader seconds the motion. Roll call was taken and the motion passed to only prefer lorazepam and buspirone.

Committee recommendations for the PDL are:

- buspirone
- lorazepam

Bile Salts

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ursodiol 300 mg capsule

Bronchodilators

Dr. Wolfson makes the motion to accept, Dr. Figueroa seconds the motion. Roll call was taken and the amended motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Albuterol nebulizer solutions – all strengths
- Foradil
- Striverdi Respimat
- ProAir HFA
- Proventil HFA
- Albuterol tab/syrup
- Terbutaline oral

COPD

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. After discussion, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Atrovent HFA
- Combivent Respimat
- Ipratropium nebulizer
- Ipratropium/Albuterol combination nebulizer
- Spiriva

Cytokine Antagonists

Dr. Figueroa makes the motion to accept, Dr. Wolfson seconds the motion. After pharmaceutical manufacturers' representatives spoke, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Enbrel
- Humira

Emollients

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ammonium lactate cream/lotion
- Lactic Acid cream/lotion

Glucocorticoids, Inhaled

Dr. Figueroa makes the motion to accept, Dr. Mader seconds the motion. After much discussion, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Advair Diskus
- Asmanex
- Dulera
- Flovent Diskus/HFA
- Pulmicort Respules 0.25 mg and 0.5 mg
- Qvar
- Symbicort

Histamine II Receptor Blockers

Dr. Figueroa moved to accept the list, Dr. Deyo seconded. Dr. Givler amended the motion to remove cimetidine from the preferred products. Dr. Orlando seconded. There was some discussion, roll was taken and the motion with the amendment passed unanimously.

Committee recommendations for the PDL are:

- Famotidine tabs
- Ranitidine syrup and tabs

Immunomodulators, Atopic Dermatitis

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. With no discussion and no speakers, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Elidel

Immunomodulators, Topical

Dr. Orlando moved to accept, Dr. Figueroa seconded. After a brief discussion, roll call was taken and the motion passed unanimously.

Committee recommendations for the PDL are:

- Aldara

Intranasal Rhinitis Agents

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Astepro
- Fluticasone
- Ipratropium nasal
- Nasonex
- Patanase

Leukotriene Modifiers

Dr. Wolfson makes the motion to accept, Dr. Figueroa seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Montelukast tab/chew tab
- Zafirlukast

Neuropathic Pain

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. After discussion and a speaker on Lyrica, and an amendment to add Neurontin (Brand name) solution to the PDL, roll call was taken and the original motion passed with a unanimous vote. Much discussion over pushing to get information on bids/offers, the federal law that forbids this information release is: 42 U.S.C. 1396 r8 (b)3(d) of the Social Security Act.

Committee recommendations for the PDL are:

- Cymbalta
- Gabapentin caps
- Lidoderm
- Neurontin solution

NSAIDS

Dr. Wolfson makes the motion to accept, Dr. Givler seconds the motion. After no pharmaceutical manufacturers' requests to make presentations and brief discussion around meloxicam, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Diclofenac potassium and SR
- Diclofenac sodium
- Flurbiprofen
- Ibuprofen and susp
- Indocin susp
- Indomethacin caps
- Ketoprofen
- Ketorolac
- Meloxicam and susp
- Nabumetone
- Naproxen and susp and naproxen EC
- Naproxen sodium
- Oxaprozin
- Sulindac

Ophthalmic Antibiotics/Steroids Combination

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- TobraDex suspension
- Neomycin/polymyxin B/Dexamethasone combination
- TobraDex ointment
- Sulfacetamide/Prednisolone combination

Ophthalmic Antibiotics

Dr. Orlando makes the motion to accept, Dr. Figueroa seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the **PDL** are:

- Bacitracin/polymyxin B sulfate oint
- Bleph-10
- Ciprofloxacin soln
- Erythromycin
- Gentamicin drops/oint
- Moxeza
- Ofloxacin
- Neomycin/polymyxin/gramicidin
- Polymyxin/trimethoprim
- Sulfacetamide soln
- Tobramycin
- Tobrex oint
- Vigamox

Ophthalmics for Allergic Conjunctivitis

Dr. Wolfson makes the motion to accept, Dr. Harris seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Alrex
- Cromolyn
- Pataday

Ophthalmic Anti-inflammatories

Dr. Wolfson makes the motion to accept, Dr. Figueroa seconds the motion. There are no speakers. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Dexamethasone
- Diclofenac
- Durezol
- Fluorometholone
- Flurbiprofen
- Ketorolac and LS

Ophthalmics, Glaucoma Agents

Dr. Wolfson makes the motion to accept, Dr. Givler seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the **PDL** are:

- Alphagan P 0.15%
- Betaxolol
- Brimonidine
- Carteolol
- Combigan
- Dorzolamide and Dorzolamide/timolol
- Latanoprost 2.5 mL
- Levobunolol
- Metipranolol
- Pilocarpine
- Simbrinza
- Timolol
- Travatan-Z

Otic Anti-infectives

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Acetic Acid
- Acetic Acid/Aluminum
- Antipyrine/Benzocaine combination

Otic Antibiotics

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Ciprodex
- Neomycin/Polymyxin/Hydrocortisone solution suspension
- Ofloxacin

Sedative Hypnotics

Dr. Figueroa made a motion, Dr. Wolfson seconded the motion. After discussion and no presentation, roll call was taken and the motion passed.

Committee recommendations for the PDL are:

- Temazepam
- Triazolam
- Zolpidem

Smoking Cessation

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed.

Committee recommendations for the PDL are:

- Bupropion SR
- Chantix and Chantix Dose Pack
- Nicorette gum and lozenge
- Nicotine gum, lozenge, patch

Steroids Topical, High Potency

Dr. Figueroa makes the motion to accept, Dr. Orlando seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Betamethasone dipropionate cream/lotion
- Betamethasone val cream
- Fluocinonide cream/soln/emollient
- Triamcinolone acetonide cream/ointment
- Triamex ointment

Steroids Topical, Low Potency

Dr. Figueroa makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, and a brief pricing discussion, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Alclometasone dipropionate cream/ointment
- Fluocinolone 0.01% oil
- Hydrocortisone cream/ointment/lotion/gel
- Hydrocortisone/Mineral Oil/Petrolatum combination

Steroids Topical, Medium Potency

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Betamethasone valerate foam
- Fluticasone propionate ointment/cream
- Hydrocortisone Butyrate soln
- Mometasone furoate soln/cream/ointment
- Prednicarbate cream

Steroids Topical, Very High Potency

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Clobetasol emollient
- Clobetasol propionate cream, gel, oint, soln

Stimulants and Related Agents

Dr. Wolfson makes the motion to accept, Dr. Harris seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Adderall XR
- Amphetamine Salt Combo Immediate Release
- Daytrana
- Dexmethylphenidate
- Dextroamphetamine
- Focalin
- Focalin XR
- Intuniv
- Metadate CD
- Methylphenidate IR and ER (generic for Concerta)
- ProCentra
- Quillivant XR
- Strattera
- Vyvanse

II. Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class. Eleven (11) new drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

Analgesics Narcotics, Short: Xartemis XR

Dr. Wolfson makes the motion to accept, Dr. Figueroa seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Xartemis XR

Antifungals, Topical: Jublia

Dr. Givler makes the motion to accept, Dr. Harris seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Jublia

Beta-Blockers: Hemangeol

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Hemangeol

Hypoglycemics, Incretin Mimetics and Enhancers: Bydureon Pen and Tanzeum

Dr. Figueroa makes the motion to accept, Dr. Givler seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Tanzeum
- Prefer Bydureon Pen

Hypoglycemics, SGLT2s: Jardiance and Invokana

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Invokana
- Non-prefer Jardiance

Lincosamides: Sivextro

Dr. Orlando makes the motion to accept, Dr. Figueroa seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Sivextro

Opiate Dependence Treatments: Evzio

Dr. Orlando makes the motion to accept, Dr. Figueroa seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Evzio

PAH Agents Oral and Inhaled: Orenitram ER

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Orenitram ER

Platelet Aggregation Inhibitors: Zontivity

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee recommendations for the PDL are:

- Non-prefer Zontivity

Therapy classes to be reviewed for the May 2015 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as "Agenda."

Next Meeting Date

The next committee meeting is scheduled for May 6, 2015.

Adjournment

The meeting adjourned at 12:44 p.m.

Marilyn J. Chen